Vigil Neuroscience’s (VIGL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $17.00 price objective on the stock. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.52) EPS, Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($2.05) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.78 EPS.

A number of other analysts have also recently commented on the stock. JMP Securities reiterated a market outperform rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Wedbush reiterated an outperform rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research note on Thursday, July 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $16.60.

Vigil Neuroscience Trading Up 0.9 %

Vigil Neuroscience stock opened at $3.49 on Wednesday. The company has a market cap of $138.38 million, a P/E ratio of -1.65 and a beta of 2.00. Vigil Neuroscience has a 1-year low of $2.47 and a 1-year high of $9.24. The company has a fifty day simple moving average of $3.98 and a 200 day simple moving average of $3.44.

Institutional Trading of Vigil Neuroscience

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Vigil Neuroscience by 11.9% during the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Vigil Neuroscience by 72.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the 2nd quarter worth about $87,000. Finally, Strs Ohio acquired a new stake in shares of Vigil Neuroscience during the 4th quarter worth about $27,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.